Severity assessment of single-dose oxford-astra zeneca vaccinated individuals infected with SARS CoV-2 in Southeast Bangladesh

Coronavirus disease (COVID-19) vaccination campaign is underway in several parts of the planet including Bangladesh but till to this point there’s
no available health data revealed among the vaccinated people. We conducted a cross-sectional study to assess the health status of 1st dose Oxford-
AstraZeneca vaccinated individuals infected with SARS CoV-2. Standard virological method real-time reverse transcriptase-polymerase chain
reaction (RT-qPCR) was performed to detect SARS-CoV-2 and different health parameters from vaccinated individuals were collected using prestructured
questionnaires during infection period. A total of 6146 suspected samples were tested and 1752 were found positive for SARS-CoV-2,
of them 200 individuals were identified who received 1st dose of COVID-19 vaccine. Among the vaccinated individuals, 165 (82.5%) patients were
not hospitalized and 177 (88.5%) did not show any respiratory difficulties. Only 8% of patients required extra oxygen support and 199 (99.5%)
individuals didn’t desiderate any intensive care unit (ICU) interference. Overall, oxygen saturation was recorded around 96.8% and respiratory
difficulties did not extend more than 5 days during the infection period. Within the vaccinated COVID-19 positive individuals 113 (56.5%) and
111(55.5%) persons have normal physiological taste and smell. Surprisingly, 129 (64.5%) individuals carrying different comorbidity where high
blood pressure 36 (27.9%) and diabetes 32 (24.8%) were found more prevalent. However, the significant finding of the present study was 199
(99.5%) vaccinated individuals survived with good health conditions and became negative with subsequent RT-qPCR test. The results of this study
expound that administration of 1st dose Oxford-AstraZeneca vaccine significantly reduces health risks during the COVID-19 infection period.